Credit Suisse: Dr. Reddy's Labs Upgraded to 'Outperform' From 'Neutral' on Expectations of Strong US Sale Outlook

December 13, 2012 8:31 AM GMT

  • FOLLOW IBT: YOUR ONE-STOP NEWS SITE
  • Google Plus
(Photo: Reuters)<br>Dr. Reddy&#039;s Labs Upgraded by Credit Suisse
(Photo: Reuters)
Dr. Reddy&#039;s Labs Upgraded by Credit Suisse

Credit Suisse upgrades Dr. Reddy's Laboratories(REDY.NS) to 'outperform' from 'neutral' and raises its target price to 2,150 rupees from 1,900 rupees, citing expectations for a strong pick up in U.S. sales in the coming quarters.

Share article

Credit Suisse also notes the market share for Dr. Reddy's Metoprolol drug, used for hypertension, is increasing.

  • FOLLOW IBTIMES
  • Google Plus

Dr. Reddy's also expects upcoming approval of two limited competition products in the United States, Credit Suisse says after meeting with the drug maker's management.

Dr. Reddy's also expects fiscal 2015 growth in the United States to be stronger than fiscal 2014 due to some "significant" launches.

Copyright 2012 Thomson Reuters. All rights reserved.
Join the Conversation
Universal Credit: UK benefits shake-up begins